Author, as appears in the article.: Carbonell, R; Moreno, G; Martin-Loeches, I; Bodi, M; Rodriguez, A

Department: Medicina i Cirurgia

URV's Author/s: Rodríguez Oviedo, Alejandro Hugo

Keywords: Antibiotic-therapy Bacterial respiratory co-infection Biomarkers C-reactive protein Calcitonin-i gene Care Covid-19 Infections Influenza pneumonia Lower respiratory-tract Marker Procalcitonin Procalcitonin concentrations Prognosis Prognostic value Sars-cov-2 Ventilator-associated pneumonia

Abstract: Pneumonia is a growing problem worldwide and remains an important cause of morbidity, hospitalizations, intensive care unit admission and mortality. Viruses are the causative agents in almost a fourth of cases of community-acquired pneumonia (CAP) in adults, with an important representation of influenza virus and SARS-CoV-2 pneumonia. Moreover, mixed viral and bacterial pneumonia is common and a risk factor for severity of disease. It is critical for clinicians the early identification of the pathogen causing infection to avoid inappropriate antibiotics, as well as to predict clinical outcomes. It has been extensively reported that biomarkers could be useful for these purposes. This review describe current evidence and provide recommendations about the use of biomarkers in influenza and SARS-CoV-2 pneumonia, focusing mainly on procalcitonin (PCT) and C-reactive protein (CRP). Evidence was based on a qualitative analysis of the available scientific literature (meta-analyses, randomized controlled trials, observational studies and clinical guidelines). Both PCT and CRP levels provide valuable information about the prognosis of influenza and SARS-CoV-2 pneumonia. Additionally, PCT levels, considered along with other clinical, radiological and laboratory data, are useful for early diagnosis of mixed viral and bacterial CAP, allowing the proper management of the disease and adequate antibiotics prescription. The authors propose a practical PCT algorithm for clinical decision-making to guide antibiotic initiation in cases of influenza and SARS-CoV-2 pneumonia. Further well-design studies are needed to validate PCT algorithm among these patients and to confirm whether other biomarkers are indeed useful as diagnostic or prognostic tools in viral pneumonia.

Thematic Areas: Biochemistry Engenharias ii General pharmacology, toxicology and pharmaceutics Infectious diseases Microbiology Microbiology (medical) Pharmacology & pharmacy Pharmacology (medical) Pharmacology, toxicology and pharmaceutics (all) Pharmacology, toxicology and pharmaceutics (miscellaneous)

licence for use: https://creativecommons.org/licenses/by/3.0/es/

Author's mail: alejandrohugo.rodriguez@urv.cat

Author identifier: 0000-0001-8828-5984

Record's date: 2023-05-13

Papper version: info:eu-repo/semantics/publishedVersion

Link to the original source: https://www.mdpi.com/2079-6382/12/1/161

Papper original source: Antibiotics. 12 (1):

APA: Carbonell, R; Moreno, G; Martin-Loeches, I; Bodi, M; Rodriguez, A (2023). The Role of Biomarkers in Influenza and COVID-19 Community-Acquired Pneumonia in Adults. Antibiotics, 12(1), -. DOI: 10.3390/antibiotics12010161

Licence document URL: http://repositori.urv.cat/ca/proteccio-de-dades/

Article's DOI: 10.3390/antibiotics12010161

Entity: Universitat Rovira i Virgili

Journal publication year: 2023

Publication Type: Journal Publications